Sponsors (3)
The bill strengthens FDA oversight and speeds safety-related reporting and validation to protect patients and improve reprocessing standards, but it imposes significant compliance costs and timing rules that may raise prices, complicate reporting for small manufacturers, and risk temporary shortages or delayed device improvements.
Hospitals, clinicians, and patients receive faster federal notice of device design/reprocessing changes and foreign safety communications, enabling the FDA to act sooner and reducing patient exposure to unsafe devices.
Validated instructions and standardized validation requirements for reusable-device reprocessing and rapid assessment tests improve safe reprocessing practices, lowering infection risk for patients and creating clearer protocols for healthcare facilities.
Creates stronger regulatory incentives and an enforcement tool (adulteration designation) to hold manufacturers accountable and encourage consistent cross-border reporting of safety-relevant communications, improving overall information flow and accountability.
Manufacturers — especially small firms — face higher compliance, testing, and legal costs to prepare pre-change notices, validate reprocessing tests, and meet faster reporting timelines, which is likely to raise device prices.
If the FDA uses adulteration designations or existing products fail the new validation requirements, patients and providers could face supply disruptions, recalls, or temporary shortages of needed devices or reprocessing tests.
Tighter timelines (e.g., a 5-day window for reporting foreign communications) and a broad affiliate definition increase legal and administrative complexity, disproportionately burdening smaller manufacturers with tracking and reporting obligations.
Based on analysis of 4 sections of legislative text.
Requires manufacturers to notify HHS/FDA before device design or reprocessing instruction changes, report certain foreign communications in 5 days, and supply validated instructions for listed rapid reprocessing tests.
Introduced March 26, 2025 by Ted Lieu · Last progress March 26, 2025
Requires device manufacturers to notify the Department of Health and Human Services (through FDA) before changing device designs or reprocessing instructions and to report certain widely shared communications to foreign health providers within five days. Violations can cause a device to be treated as “adulterated,” and certain rapid reprocessing assessment tests must include validated instructions and data before FDA will accept notifications. The bill expands the federal device definitions to explicitly cover rapid assessment tests for reusable devices, defines reusable devices, and gives the Secretary one year to publish a list of test types that need validation data; manufacturers face new paperwork, validation, and legal risk for noncompliance, while hospitals, health workers, and patients may see improved safety but potential delays in device updates or communications.